Zydus launches biosimilar Zyrifa for cancer patients' bone health

Zydus Lifesciences Ltd. announced the launch of Zyrifa, a biosimilar Denosumab 120 mg SC, on December 10, 2025. This therapy aims to reduce and delay Skeletal Related Events (SREs) across solid tumors and multiple myeloma, offering a new treatment option for cancer patients with bone metastases. The new biosimilar is priced at an MRP of Rs 12,495.

Denosumab is a monoclonal antibody addressing bone health, primarily for osteoporosis and preventing skeletal complications in cancer patients. It targets bone metastases caused by various cancers, including breast, prostate, lung, and myeloma. Bone metastases significantly impact patient quality of life, leading to pain, fractures, and reduced mobility.

The launch underscores Zydus Lifesciences' commitment to providing accessible and affordable medication for critical care cancer patients, helping them retain mobility. The company continues to expand its portfolio of biosimilars for various cancers.